|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
03-22-2010, 01:39 PM
|
|||
|
|||
Spectrum Pharmaceuticals Announces a National Cancer Institute-Sponsored Phase 1/2 St
IRVINE, Calif.----Spectrum Pharmaceuticals, Inc. , a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Neotropix Announces Enrollment of Patients in NCI-Sponsored Phase II Clinical Trial f | cancerfr | Lung Cancer | 0 | 05-14-2010 01:57 PM |
| Celator(R) Pharmaceuticals Announces Positive Data From Phase 2 Study of CPX-351 in A | cancerfr | Leukemia | 0 | 05-03-2010 06:10 PM |
| Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2009 Corporate Upda | cancerfr | Adrenocortical Carcinoma | 0 | 04-05-2010 12:29 PM |
| Portola Pharmaceuticals Announces Initiation Of Phase 1 Clinical Trial Of PRT062607, | cancerfr | Non-Hodgkin Lymphoma | 0 | 03-24-2010 03:38 PM |
| Spectrum Pharmaceuticals Announces a National Cancer Institute-Sponsored Phase 1/2 St | cancerfr | Oral Cancer | 0 | 03-22-2010 01:39 PM |
Linear Mode
